Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Candace Ryan

Physician Assistant Glendale, AZ Physician Assistant

NPI 1538337555 CMS profile 11024568

5601 W. Eugie Ave., Suite 204, Glendale, AZ 85304

Open in the dashboard

General payments

$112,506

1,006 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Candace Ryan of Glendale, AZ is reported in the CMS Open Payments database as having received $112,506 across 1,006 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $24,968 197
2024 General $35,761 232
2023 General $38,498 237
2022 General $8,723 173
2021 General $4,557 167

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Candace Ryan
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Candace Ryan were reported at $24,968. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Candace Ryan Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $4,557 $132 $37–$438 $132
2022 $8,723 $155 $48–$522 $149
2023 $38,498 $167 $52–$557 $160
2024 $35,761 $178 $55–$600 $164
2025 $24,968 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $32,784 103 payments
  2. Lilly USA, LLC $25,133 113 payments
  3. Genzyme Corporation $19,954 53 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $10,701 32 payments
  5. Novartis Pharmaceuticals Corporation $8,038 52 payments
  6. AbbVie, Inc. $3,973 181 payments
  7. UCB, Inc. $2,460 78 payments
  8. Amgen Inc. $2,261 92 payments
  9. Pfizer Inc. $1,484 94 payments
  10. Fresenius Kabi USA, LLC $1,306 8 payments
  11. Other $4,413 200 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $56,079 50 payments
  2. Food and Beverage $21,986 885 payments
  3. Consulting Fee $18,665 12 payments
  4. Travel and Lodging $15,452 54 payments
  5. Education $324 5 payments
Products named General payments · program years 2021–2025
  1. SAPHNELO $30,323 78 payments
  2. TALTZ $22,003 107 payments
  3. KEVZARA $19,992 53 payments
  4. COSENTYX $7,472 31 payments
  5. CYLTEZO $5,544 10 payments
  6. OFEV $4,071 11 payments
  7. RINVOQ $3,153 144 payments
  8. Cimzia $1,705 56 payments
  9. XELJANZ $1,430 91 payments
  10. IDACIO $1,281 7 payments
  11. Other $12,151 564 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,042

Median for Physician Assistant: 241

Drug cost

$395,417

Median for Physician Assistant: $4,110

Branded share of claims

20.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rinvoq Upadacitinib Brand 47 $373,252
Methotrexate Methotrexate Sodium Brand 152 $4,591
Hydroxychloroquine Sulfate Generic 88 $4,299
Tramadol Hcl Generic 226 $2,352
Azathioprine Generic 11 $1,711
Pilocarpine Hcl Generic 19 $1,611
Gabapentin Generic 61 $1,262
Pregabalin Generic 30 $1,044
Leucovorin Calcium Generic 64 $713
Duloxetine Hcl Generic 26 $683

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SAPHNELO
$17,686 — —
KEVZARA
$5,095 — —
OFEV
$4,071 — —
TALTZ
$3,169 — —
COSENTYX
$1,551 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

1,006 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record